Rudin CM, Poirier JT, Byers LA et al (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19(5):289–297

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baine MK, Hsieh MS, Lai WV et al (2020) SCLC Subtypes Defined by ASCL1, NeuroD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thoracic Oncol 15(12):1823–1835

Article  CAS  Google Scholar 

Owonikoko TK, Dwivedi B et al (2020) YAP1 expression in small cell lung cancer defines a distinct subtype with T-cell inflamed phenotype. J Thoracic Oncol 4(20):31028–31025

Google Scholar 

Tlemsani C, Pongor L, Elloumi F et al (2020) SCLC-cell miner: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures. Cell Rep 33(3):108296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planchard D, Popat S, Kerr K et al (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237

Article  CAS  PubMed  Google Scholar 

Solomon JP, Benayed R, Hechtman JF et al (2019) Identifying patients with NTRK fusion cancer. Ann Oncol 30(Suppl_8):16–22

Article  Google Scholar 

Tambo Y, Sone T, Kasahara K et al (2017) Combination treatment using an EGFR tyrosine kinase inhibitor plus platinum-based chemotherapy for a patient with transformed small cell carcinoma and EGFR-mutated lung adenocarcinoma. J Thoracic Oncol 12(12):199–200

Article  Google Scholar 

Pignataro D, Bertaglia V, Bironzo P et al (2020) Oligoprogressive disease with SCLC transformation in EGFR-mutated NSCLC: how biology knowledge can change the game rules. J Thorac Oncol 15(10):e170–e172

Article  CAS  PubMed  Google Scholar 

Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–2247

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi X, Duan H, Liu X et al (2016) Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors. Oncotarget 7(23):34240–34249

Article  PubMed  PubMed Central  Google Scholar 

Oser MG, Niederst MJ, Sequist LV et al (2015) Transformation from nonsmall-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 16(4):e165–e172

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roca E, Gurizzan C, Amoroso V et al (2017) Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis. Cancer Treat Rev 59:117–122

Article  CAS  PubMed  Google Scholar 

Gay CM, Stewart CA, Park EM et al (2021) Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346-360.e7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Wu S, Li Z et al (2023) Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies. Cancer Sci 114(2):665-679

Megyesfalvi Z, Barany N, Lantos A et al (2022) Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. J Pathol 257(5):674–686

Article  CAS  PubMed  PubMed Central  Google Scholar 

Augert A, Eastwood E, Ibrahim AH et al (2019) Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal 12(567):eaau2922

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hermans BCM, Derks JL, Thunnissen E et al (2019) DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. Lung Cancer 138:102–108

Article  CAS  PubMed  Google Scholar 

Xie H, Boland JM, Maleszewski JJ et al (2019) Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. Lung Cancer 135:73–79

Article  PubMed  Google Scholar 

Konstantakou EG, Velentzas AD, Anagnostopoulos AK et al (2017) Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: from oncogenic addiction to druggable targets. PLoS ONE 12:e0171512

Article  PubMed  PubMed Central  Google Scholar 

Spino M, Kurz SC, Chiriboga L et al (2019) Cell surface notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase-mutant glioma. Clin Cancer Res 25:1261–1271

Article  CAS  PubMed  Google Scholar 

Leonetti A, Facchinetti F, Minari R et al (2019) Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Cell Oncol (Dordr) 42:261–273

Article  CAS  PubMed  Google Scholar 

Hu C, Dong J, Liu L et al (2022) ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: a study of 247 cases from the National Cancer Center of China. Thorac Cancer 13(3):338–345

Article  CAS  PubMed  Google Scholar 

Laura S, Alexander B, Wade A et al (2015) Research article. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7(302):302ra136

Google Scholar 

Neptune ER, Podowski M, Calvi C et al (2008) Targeted disruption of NeuroD1, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung. J Biol Chem 283(30):21160–21169

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borromeo MD, Savage TK, Kollipara RK et al (2016) ASCL1 and NeuroD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep 16(5):1259–1272

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pearsall SM, Humphrey S, Revill M et al (2020) The Rare YAP1 Subtype of SCLC revisited in a biobank of 39 circulating tumor cell patient derived explant models: A brief report. J Thorac Oncol 15(12):1836–1843

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mollaoglu G, Guthrie MR, Böhm S et al (2017) MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell 31:270–285

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ireland AS, Micinski AM, Kastner DW et al (2020) MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell 38:60-78.e12

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyakawa K, Miyashita N, Horie M et al (2022) ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer. Cancer Sci 113(11):3932–3946

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujino K, Motooka Y, Hassan WA et al (2015) Insulinoma- associated protein 1 is a crucial regulator of neuroendocrine differentiation in lung cancer. Am J Pathol 185:3164–3177

Article  CAS  PubMed  Google Scholar 

Lantuejoul S, Fernandez-Cuesta L, Damiola F et al (2020) New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Transl Lung Cancer Res 9(5):2233–2244

Article  CAS  PubMed  PubMed Central